US · NEPH
Nephros, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- South Orange, NJ 07079
- Website
- nephros.com
Price · as of 2024-12-31
$3.11
Market cap 41.55M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $256.17 | +8,136.98% |
| Intrinsic Value(DCF) | $11.07 | +255.95% |
| Graham-Dodd Method(GD) | $0.78 | -74.95% |
| Graham Formula(GF) | $0.05 | -98.3% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $5.40 | $2,726.72 | $40.63 | $0.00 | $0.00 |
| 2011 | $8.73 | $19.59 | $0.00 | $0.00 | $37.84 |
| 2012 | $8.46 | $26.43 | $0.00 | $0.00 | $24.77 |
| 2013 | $4.41 | $52.12 | $0.00 | $0.00 | $0.00 |
| 2014 | $5.94 | $153.32 | $0.00 | $0.00 | $0.00 |
| 2015 | $3.33 | $48.30 | $0.00 | $0.00 | $0.00 |
| 2016 | $4.50 | $122.14 | $0.00 | $0.00 | $0.00 |
| 2017 | $4.32 | $280.39 | $0.12 | $0.00 | $0.00 |
| 2018 | $5.04 | $301.04 | $2.09 | $0.00 | $0.00 |
| 2019 | $8.35 | $78.97 | $1,399.64 | $0.00 | $0.00 |
| 2020 | $7.51 | $56.95 | $95.75 | $0.00 | $4.37 |
| 2021 | $4.00 | $123.61 | $40.38 | $0.00 | $0.00 |
| 2022 | $0.97 | $37.17 | $0.00 | $0.00 | $0.00 |
| 2023 | $2.70 | $201.81 | $12.77 | $0.00 | $0.00 |
| 2024 | $1.65 | $256.17 | $0.22 | $0.78 | $0.05 |
AI valuation
Our deep-learning model estimates Nephros, Inc.'s (NEPH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $256.17
- Current price
- $3.11
- AI upside
- +8,136.98%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$11.07
+255.95% upside
Graham-Dodd
$0.78
-74.95% upside
Graham Formula
$0.05
-98.3% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NEPH | Nephros, Inc. | $3.11 | 41.55M | +8,137% | +256% | -75% | -98% | 234.68 | 2.02 | 1.23 | 66.16 | — | 2.39 | 61.59% | 0.04% | 0.52% | 0.87% | 0.08% | 0.64% | 0.16 | 6.00 | 5.31 | 3.55 | -10.35 | -10467.00% | -53.00% | -17274.00% | -3.15% | -0.31 | -9.02% | 0.00% | 0.00% | 0.00% | 2502.93 | -27.45 | 1.06 | -12.07 |
| BEAT | HeartBeam, Inc. | $1.51 | 52.01M | — | — | — | — | -3.00 | 35.28 | — | -2.82 | -216.03 | 35.28 | 0.00% | — | — | -221.11% | 4079.38% | -190.60% | 0.00 | — | 1.71 | 1.47 | 0.12 | 139.00% | — | 1881.00% | -25.14% | -8.92 | 3009.64% | 0.00% | 0.00% | 0.00% | -2.81 | -3.82 | — | -22.07 |
| DXR | Daxor Corporation | $11.86 | 59.76M | +2,657% | +20% | -33% | — | 72.23 | 1.08 | 18.18 | 19.18 | 88.61 | 1.08 | 100.00% | 29.16% | 25.17% | 1.54% | 1.74% | 1.50% | 0.02 | 7.30 | 0.17 | 0.09 | 0.35 | 8152.00% | -9384.00% | -10070.00% | 0.07% | 0.23 | 0.07% | 0.00% | 0.00% | 0.07% | 63.52 | 1536.03 | 18.52 | 28.75 |
| HOWL | Werewolf Therapeutics, In… | $0.60 | 29.13M | +4,114% | — | — | +21,192% | -0.76 | 0.73 | 28.28 | 0.32 | -1.37 | 0.73 | 3.77% | -3904.19% | -3740.85% | -76.33% | -517.61% | -46.74% | 0.51 | -15.81 | 7.45 | 7.31 | 1.15 | 5524.00% | -9055.00% | 6908.00% | -105.90% | -3.70 | -396.98% | 0.00% | 0.00% | 0.00% | 0.28 | 0.37 | -10.93 | -4.95 |
| ICCC | ImmuCell Corporation | $6.57 | 59.43M | +3,272% | -69% | -69% | — | -19.35 | 1.52 | 1.58 | 49.76 | — | 1.52 | 29.97% | -6.19% | -8.14% | -8.22% | -4.12% | -4.85% | 0.55 | -2.88 | 3.41 | 1.72 | 10.63 | -6533.00% | 5164.00% | -9836.00% | -0.26% | 0.08 | -0.27% | 0.00% | 0.00% | 10.47% | -32.36 | -492.25 | 2.00 | 1.73 |
| NRXP | NRx Pharmaceuticals, Inc. | $1.86 | 32.15M | — | — | — | — | -0.91 | -0.98 | — | -1.16 | — | -0.98 | 0.00% | — | — | 143.76% | 156.03% | -458.25% | -0.28 | -18.26 | 0.15 | 0.07 | -0.21 | -3995.00% | — | -5089.00% | -46.61% | -0.49 | 84.23% | 0.00% | 0.00% | 0.00% | -1.42 | -2.63 | — | -130.11 |
| ONMD | OneMedNet Corporation | $1.02 | 33.44M | +2,413% | -71% | — | +864% | -2.08 | -1.32 | 32.79 | -2.70 | — | -1.32 | -43.70% | -1493.78% | -1575.27% | 70.32% | 106.64% | -483.48% | -0.55 | -65.34 | 0.19 | 0.17 | -0.87 | -9245.00% | -3702.00% | 4548.00% | -33.36% | -0.36 | 78.10% | 0.00% | 0.00% | 0.95% | -2.79 | -3.81 | 41.72 | -50.87 |
| OTLK | Outlook Therapeutics, Inc… | $0.42 | 17.31M | — | +90,898,778% | — | — | 0.00 | 0.00 | 50.46 | 123242.30 | — | 0.00 | 46.49% | -4744.25% | -4416.22% | 387.88% | 0.00% | -671.81% | -0.01 | -236.86 | 0.38 | 0.18 | 123243.42 | -5591.00% | — | 7534010988.00% | -72659652.79% | -1.13 | 259.00% | 0.00% | 0.00% | 10984444.51% | 116837.47 | 0.15 | -5543064.49 | -47.47 |
| SPRB | Spruce Biosciences, Inc. | $54.94 | 31.88M | +1,366% | +1,346% | — | +7,284% | -20.08 | 36.96 | 216.90 | -19.54 | -498.08 | 36.96 | 100.00% | -1143.37% | -1079.94% | -100.70% | 501.62% | -71.12% | 0.10 | -182.90 | 2.90 | 2.54 | 0.68 | 403.00% | -5132.00% | 6815.00% | -5.25% | -3.67 | 499.95% | 0.00% | 0.00% | 0.00% | -18.33 | -18.39 | 209.57 | 28.03 |
| ZJYL | Jin Medical International… | $0.15 | 22.71M | +27,605% | +31% | +56% | — | 26.97 | 1.26 | 1.80 | 28.45 | — | 1.31 | 29.22% | 2.94% | 5.76% | 4.73% | 3.23% | 2.79% | 0.64 | — | 1.86 | 1.53 | 12.27 | -6766.00% | -1198.00% | 5982.00% | -10.00% | 0.12 | -22.87% | 0.00% | 0.00% | 0.00% | 43.64 | -7.12 | 1.28 | 2.37 |
About Nephros, Inc.
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
- CEO
- Robert Banks
- Employees
- 31
- Beta
- 1.41
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($11.07 ÷ $3.11) − 1 = +255.95% (DCF, example).